About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality.

Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology.

Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Overview of Role: The Director, Portfolio Strategy position reports to the Executive Director, Portfolio Strategy and Competitive Intelligence to support strategic planning activities by providing actionable recommendations based on assessments of markets and competitors, both existing and potential.

Responsibilities

g. Clinical, Regulatory, Commercial) to guide Summit’s portfolio for late-stage clinical development strategy Develop/refine framework and process for the New indication and overall portfolio strategy, providing thought leadership and supporting key strategic decision-making and investment decisions Deliver strategic market and competitive intelligence insights through research, scenario planning, and impact assessments to guide executive decision-making and Summit’s portfolio strategy. Deliver Disease Area strategy for new solid tumor indications by providing an overall integrated strategy and market assessment in partnership with R D, Clinical, Medical, Commercial and Program teams Partner with BD team to provide strategic direction and guidance on business development opportunities Conduct deep analysis of competitors, products, and market trends, maintaining real-time awareness of landscape changes and translating insights into strategic implications for launch and also for pipeline indications Develop, lead and execute comprehensive market research plans (qualitative, quantitative, and competitive), selecting vendors, designing studies, interpreting results, and ensuring timely, high-quality deliverables.

Develop NPV, forecasting and revenue modeling for new indications up to 18 months before launch, providing data-driven assumptions for early commercial planning.